| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
180,310,000 |
| Market
Cap: |
41.24(B) |
| Last
Volume: |
799,597 |
Avg
Vol: |
865,759 |
| 52
Week Range: |
$191.51 - $228.9 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Seagen is a biotechnology company that develops and commercializes targeted therapies to treat cancer. Co. is commercializing ADCETRIS®, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas, PADCEV®, or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, TIVDAK™, or tisotumab vedotin-tftv, for the treatment of certain metastatic cervical cancers, and TUKYSA®, or tucatinib, for treatment of certain metastatic HER2-positive breast cancers. Co. is also developing a pipeline of therapies for solid tumors and blood-related cancers designed to address unmet medical needs and improve treatment outcomes for patients.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
39,326 |
485,736 |
| Total Sell Value |
$0 |
$0 |
$8,245,949 |
$88,282,436 |
| Total People Sold |
0 |
0 |
7 |
8 |
| Total Sell Transactions |
0 |
0 |
18 |
71 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Orwin John A |
Director |
– • – |
2020-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
1,335 |
26,098 |
|
- |
|
| Welch Daniel G |
Director |
– • – |
2020-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
1,335 |
56,598 |
|
- |
|
| Akkaraju Srinivas |
Director |
– • – |
2020-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
1,335 |
41,503 |
|
- |
|
| Simonian Nancy A |
Director |
– • – |
2020-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
1,335 |
26,098 |
|
- |
|
| Gryska David W |
Director |
– • – |
2020-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
1,335 |
49,348 |
|
- |
|
| Romp Charles R |
EVP, Commercial |
• – – |
2020-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
3,444 |
56,019 |
|
- |
|
| Lippman Marc E |
Director |
– • – |
2020-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
1,335 |
131,648 |
|
- |
|
| Baker Julian |
Director |
– • • |
2020-05-15 |
4 |
A |
$0.00 |
$0 |
I/I |
2,670 |
43,290,171 |
|
- |
|
| Baker Julian |
Director |
– • • |
2020-05-15 |
4 |
S |
$160.00 |
$280,000,000 |
I/I |
(1,750,000) |
43,288,836 |
|
-17% |
|
| Seth Alpna |
Director |
– • – |
2020-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
1,335 |
10,048 |
|
- |
|
| Romp Charles R |
EVP, Commercial |
• – – |
2020-05-12 |
4 |
S |
$166.00 |
$1,152,372 |
D/D |
(6,942) |
52,575 |
|
-13% |
|
| Romp Charles R |
EVP, Commercial |
• – – |
2020-05-12 |
4 |
OE |
$15.46 |
$107,323 |
D/D |
6,942 |
59,517 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2020-05-08 |
4 |
AS |
$160.02 |
$4,584,311 |
D/D |
(28,472) |
718,339 |
|
15% |
|
| Siegall Clay B |
President and CEO |
• • – |
2020-05-08 |
4 |
OE |
$12.00 |
$341,664 |
D/D |
28,472 |
719,439 |
|
- |
|
| Baker Julian |
Director |
– • • |
2020-05-08 |
4 |
S |
$158.50 |
$79,250,000 |
I/I |
(500,000) |
44,891,148 |
|
-15% |
|
| Romp Charles R |
EVP, Commercial |
• – – |
2020-05-08 |
4 |
S |
$163.02 |
$1,131,667 |
D/D |
(6,942) |
52,575 |
|
-15% |
|
| Romp Charles R |
EVP, Commercial |
• – – |
2020-05-08 |
4 |
OE |
$15.46 |
$107,323 |
D/D |
6,942 |
59,517 |
|
- |
|
| Baker Julian |
Director |
– • • |
2020-05-07 |
4 |
S |
$163.41 |
$27,660,947 |
I/I |
(168,244) |
45,348,951 |
|
-13% |
|
| Dansey Roger D |
Chief Medical Officer |
• – – |
2020-05-07 |
4 |
S |
$164.50 |
$1,959,526 |
D/D |
(11,912) |
117,233 |
|
-13% |
|
| Dansey Roger D |
Chief Medical Officer |
• – – |
2020-05-07 |
4 |
OE |
$65.11 |
$775,590 |
D/D |
11,912 |
129,145 |
|
- |
|
| Baker Julian |
Director |
– • • |
2020-05-06 |
4 |
S |
$164.06 |
$64,379,473 |
I/I |
(390,072) |
45,502,996 |
|
-13% |
|
| Welch Daniel G |
Director |
– • – |
2020-05-06 |
4 |
S |
$164.21 |
$2,471,919 |
D/D |
(15,000) |
55,263 |
|
-13% |
|
| Siegall Clay B |
President and CEO |
• • – |
2020-05-06 |
4 |
S |
$163.77 |
$4,197,062 |
D/D |
(25,402) |
718,339 |
|
-13% |
|
| Welch Daniel G |
Director |
– • – |
2020-05-05 |
4 |
S |
$165.62 |
$3,334,641 |
D/D |
(20,000) |
70,263 |
|
-12% |
|
| Akkaraju Srinivas |
Director |
– • – |
2020-05-05 |
4 |
S |
$167.26 |
$1,421,710 |
D/D |
(8,500) |
40,168 |
|
-12% |
|
1805 Records found
|
|
Page 16 of 73 |
|
|
